Alglucosidase

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 250 publications

Response to: Correspondence on 'Stability of alglucosidase alfa in 0.9% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements' by Barzel et al.

Response to: Correspondence on 'Stability of alglucosidase alfa in 0.9% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements' by Barzel et al.

Journal: European journal of hospital pharmacy : science and practice

Published: December 31, 2025

Correspondence on "Stability of alglucosidase alfa in 0.9% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements" by Barzel et al.

Correspondence on "Stability of alglucosidase alfa in 0.9% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements" by Barzel et al.

Journal: European journal of hospital pharmacy : science and practice

Published: December 23, 2025

Can Alpha-Glucosidase Activity in Plasma or Leukocytes Serve as a Biomarker for Future Gene Therapy in Classic Infantile Pompe Disease?

Can Alpha-Glucosidase Activity in Plasma or Leukocytes Serve as a Biomarker for Future Gene Therapy in Classic Infantile Pompe Disease?

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: November 09, 2025

Can Alpha-Glucosidase Activity in Plasma or Leukocytes Serve as a Biomarker for Future Gene Therapy in Classic Infantile Pompe Disease?

Can Alpha-Glucosidase Activity in Plasma or Leukocytes Serve as a Biomarker for Future Gene Therapy in Classic Infantile Pompe Disease?

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: November 09, 2025

Successful desensitization to alglucosidase alfa in a very young infant with Pompe disease.

Successful desensitization to alglucosidase alfa in a very young infant with Pompe disease.

Journal: Journal of pediatric endocrinology & metabolism : JPEM

Published: October 18, 2025

Focused ultrasound delivery of enzyme replacement therapy to the brain of Gaa-/- Pompe disease mice.

Focused ultrasound delivery of enzyme replacement therapy to the brain of Gaa-/- Pompe disease mice.

Journal: Molecular genetics and metabolism

Published: August 06, 2025

Correction: Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry.

Correction: Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry.

Journal: Journal of neurology

Published: July 31, 2025

New advances in treating late-onset Pompe Disease: A narrative review.

New advances in treating late-onset Pompe Disease: A narrative review.

Journal: European journal of pediatrics

Published: July 28, 2025

Enzyme replacement therapies in adults with Pompe disease: from trials to real-world data.

Enzyme replacement therapies in adults with Pompe disease: from trials to real-world data.

Journal: Current opinion in neurology

Published: June 05, 2025

Marked Improvements in Airway Abnormalities and Multifaceted Outcomes After 2 Years Switching to Avalglucosidase Alfa: Evaluation of A 19-Year-Old Male Diagnosed With Late-Onset Pompe Disease.

Marked Improvements in Airway Abnormalities and Multifaceted Outcomes After 2 Years Switching to Avalglucosidase Alfa: Evaluation of A 19-Year-Old Male Diagnosed With Late-Onset Pompe Disease.

Journal: American journal of medical genetics. Part A

Published: May 27, 2025

Defining clinically meaningful thresholds for forced vital capacity in patients with neuromuscular disorders: Lessons learned from the COMET study in Pompe disease.

Defining clinically meaningful thresholds for forced vital capacity in patients with neuromuscular disorders: Lessons learned from the COMET study in Pompe disease.

Journal: Journal of neuromuscular diseases

Published: May 21, 2025

Cipaglucosidase alfa plus miglustat in Pompe disease: two non-ambulatory patients switching from high‑dose, high-frequency alglucosidase alfa.

Cipaglucosidase alfa plus miglustat in Pompe disease: two non-ambulatory patients switching from high‑dose, high-frequency alglucosidase alfa.

Journal: Neuromuscular disorders : NMD

Published: May 01, 2025

Showing 1-12 of 250

Last Updated: 02/24/2026